Definium Therapeutics unveils positive topline data from DT120 program at medical congress

Definium Therapeutics unveils positive topline data from DT120 program at medical congress
Definium shares DT120 clinical data

Definium Therapeutics announced it is presenting positive topline data from its DT120 clinical program for the first time on a medical congress stage.

The company will share a combined presentation of clinical updates from studies including Panorama and Emerge at the Neuroscience Education Institute Congress this week.

Definium Therapeutics has recently updated on Phase 3 studies of DT120 for depression and anxiety at a major neuropsychopharmacology event, according to a previous report. The company also announced plans to release Q3 2026 financial results following three positive Phase 3 topline results in late-stage trials, as detailed in an earlier announcement. Both updates reflect continued momentum in Definium’s clinical development programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.